Mineralys Therapeutics Adds Two Directors To Expand Board Size

RADNOR, Pa., Oct. 16, 2026. Mineralys Therapeutics, Inc. appointed Kristine Peterson and Lonnel Coats to its Board of Directors on October 16, 2026. The appointments increase the board size from seven to nine members, with both new directors taking office effective October 19, 2026.

Peterson was designated as a Class I director, a role that carries a term expiring at the company's 2027 annual meeting of stockholders. She was simultaneously appointed to serve as a member of the Audit Committee. Coats was designated as a Class II director, with a term expiring at the company's 2028 annual meeting of stockholders, and was appointed to the Compensation Committee. The Board determined that both Peterson and Coats satisfy the independence requirements set forth by The Nasdaq Stock Market LLC.

Under the company's non-employee director compensation program, each new director received specific equity grants on October 19, 2026. Peterson and Coats were each granted an option to purchase 16,600 shares of Mineralys common stock. These options vest in substantially equal monthly installments over a three-year period beginning October 19, 2026, contingent upon continued service on the Board.

Additionally, each director was granted a restricted stock unit award covering 12,400 shares of the company's common stock. These restricted stock units vest in substantially equal annual installments over a three-year period following October 19, 2026, also subject to continued service. Both directors will receive cash compensation for their board service in accordance with the company's non-employee director compensation program, which may be amended from time to time.

The company disclosed that there are no arrangements or understandings between either Peterson or Coats and any other person regarding their selection as directors. Neither director is a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K. Both individuals entered into the company's standard form of indemnification and advancement agreement. This form was previously filed as Exhibit 10.8 to the company's Registration Statement on Form S-1 with the Securities and Exchange Commission on January 18, 2023.

Mineralys Therapeutics is incorporated in Delaware and maintains its principal executive offices at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania. The company's common stock trades under the ticker symbol MLYS on The Nasdaq Stock Market LLC. The Form 8-K report was signed by Jeffrey A. Munsie, Chief Legal Officer and Secretary, on October 19, 2026.